Display options
Cite
Chen Y, Song M, Riley JP, et al. A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes. Pharmacol Res Perspect. 2016;4(6):e00278doi: 10.1002/prp2.278.
Chen, Y., Song, M., Riley, J. P., Hu, C. C., Peng, X., Scheuner, D., Bokvist, K., Maiti, P., Kahl, S. D., Montrose-Rafizadeh, C., Hamdouchi, C., & Miller, A. R. (2016). A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes. Pharmacology research & perspectives, 4(6), e00278. https://doi.org/10.1002/prp2.278
Chen, Yanyun, et al. "A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes." Pharmacology research & perspectives vol. 4,6 (2016): e00278. doi: https://doi.org/10.1002/prp2.278
Chen Y, Song M, Riley JP, Hu CC, Peng X, Scheuner D, Bokvist K, Maiti P, Kahl SD, Montrose-Rafizadeh C, Hamdouchi C, Miller AR. A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes. Pharmacol Res Perspect. 2016 Nov 21;4(6):e00278. doi: 10.1002/prp2.278. eCollection 2016 Dec. PMID: 28097011; PMCID: PMC5226292.
Copy Download .nbib Format: NLM
Share it on

Pharmacol Res Perspect. 2016 Nov 21;4(6):e00278. doi: 10.1002/prp2.278. eCollection 2016 Dec.

A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes.

Pharmacology research & perspectives

Yanyun Chen, Min Song, Jonathan P Riley, Charlie C Hu, Xianbu Peng, Donalyn Scheuner, Krister Bokvist, Pranab Maiti, Steven D Kahl, Chahrzad Montrose-Rafizadeh, Chafiq Hamdouchi, Anne Reifel Miller

Affiliations

  1. Lilly Research Laboratories Indianapolis Indiana.
  2. Jubilant BioSys Ltd. Bangalore India.

PMID: 28097011 PMCID: PMC5226292 DOI: 10.1002/prp2.278

Abstract

LY2881835 is a selective, potent, and efficacious GPR40 agonist. The objective of the studies described here was to examine the pharmacological properties of LY2881835 in preclinical models of T2D. Significant increases in insulin secretion were detected when LY2881835 was tested in primary islets from WT mice but not in islets from GPR40 KO mice. Furthermore, LY2881835 potentiated glucose stimulated insulin secretion in normal lean mice. Acute administration of LY2881835 lowered glucose during OGTTs in WT mice but not in GPR40 KO mice. These findings demonstrate that LY2881835 induces GPR40-mediated activity ex vivo and in vivo. LY2881835 was administered orally at 10 mg/kg to diet-induced obese (DIO) mice (an early model of T2D due to insulin resistance) for 14 days. Statistically significant reductions in glucose were seen during OGTTs performed on days 1 and 15. When a study was done for 3 weeks in Zucker fa/fa rats, a rat model of insulin resistance, normalization of blood glucose levels equivalent to those seen in lean rats was observed. A similar study was performed in streptozotocin (STZ)-treated DIO mice to explore glucose control in a late model of T2D. In this model, pancreatic insulin content was reduced ~80% due to STZ-treatment plus the mice were insulin resistant due to their high fat diet. Glucose AUCs were significantly reduced during OGTTs done on days 1, 7, and 14 compared to control mice. In conclusion, these results demonstrate that LY2881835 functions as a GPR40-specific insulin secretagogue mediating immediate and durable glucose control in rodent models of early- and late-stage T2D.

Keywords: FFAR1; GPCR; GPR40; hyperglycemia; insulin; type 2 diabetes

References

  1. PLoS One. 2011;6(11):e27270 - PubMed
  2. Lancet. 2012 Apr 14;379(9824):1403-11 - PubMed
  3. J Pharmacol Exp Ther. 2013 Sep;346(3):443-52 - PubMed
  4. Brain Res. 2012 Jan 13;1432:74-83 - PubMed
  5. ACS Med Chem Lett. 2012 Aug 15;3(9):726-30 - PubMed
  6. Diabetes. 2009 Nov;58(11):2607-15 - PubMed
  7. Br J Pharmacol. 2006 Jul;148(5):619-28 - PubMed
  8. Diabetologia. 2006 May;49(5):962-8 - PubMed
  9. Diabetologia. 1997 Jul;40 Suppl 2:S32-41 - PubMed
  10. Am J Physiol Endocrinol Metab. 2005 Oct;289(4):E670-7 - PubMed
  11. Pharmacol Res Perspect. 2016 Nov 21;4(6):e00278 - PubMed
  12. J Pharmacol Exp Ther. 2011 Oct;339(1):228-37 - PubMed
  13. J Biol Chem. 2003 Mar 28;278(13):11303-11 - PubMed
  14. Diabetes. 2008 Sep;57(9):2280-7 - PubMed
  15. Diabetes Obes Metab. 2012 Mar;14(3):271-8 - PubMed
  16. DNA Cell Biol. 2005 Jan;24(1):54-61 - PubMed
  17. Endocrinology. 2006 Feb;147(2):674-82 - PubMed
  18. Metabolism. 2005 Mar;54(3):296-9 - PubMed
  19. Diabetes. 2008 Aug;57(8):2211-9 - PubMed
  20. J Med Chem. 2008 Nov 27;51(22):7061-4 - PubMed
  21. J Clin Endocrinol Metab. 2008 Sep;93(9):3541-50 - PubMed
  22. Nature. 2003 Mar 13;422(6928):173-6 - PubMed
  23. Am J Physiol. 1996 Sep;271(3 Pt 1):E409-16 - PubMed

Publication Types